Nuvectis Pharma Ownership | Who Owns Nuvectis Pharma?

Nuvectis Pharma Ownership Summary

Nuvectis Pharma is owned by 7.27% institutional investors, 51.41% insiders, and 41.32% retail investors. Vanguard group is the largest institutional shareholder, holding 1.52% of NVCT shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 1.22% of its assets in Nuvectis Pharma shares.

NVCT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Nuvectis Pharma	7.27%	51.41%	41.32%
Sector	Healthcare Stocks	47.06%	8.01%	44.93%
Industry	Biotech Stocks	44.97%	7.82%	47.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Vanguard group	251.14K	1.52%	$1.59M
Baldwin brothers llc/ma	168.63K	1.02%	$1.07M
Millennium management	119.46K	0.72%	$756.17K
Blackrock	83.41K	0.50%	$528.00K
Renaissance	74.50K	0.45%	$471.58K
Goldman sachs group	61.57K	0.37%	$389.74K
Geode capital management	53.23K	0.32%	$337.00K
Northern trust	49.83K	0.30%	$315.40K
Gsa capital partners llp	48.34K	0.29%	$306.00K
Forbes j m & co llp	47.42K	0.29%	$300.16K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Baldwin brothers llc/ma	168.63K	0.08%	$1.07M
Forbes j m & co llp	47.42K	0.03%	$300.16K
Gsa capital partners llp	48.34K	0.02%	$306.00K
Baxter bros	12.50K	0.01%	$79.13K
Edmond de rothschild	19.17K	0.00%	$121.35K
Renaissance	74.50K	0.00%	$471.58K
Tower research capital llc (trc)	6.00K	0.00%	$37.95K
Millennium management	119.46K	0.00%	$756.17K
Marshall wace, llp	33.87K	0.00%	$214.38K
Two sigma investments, lp	13.04K	0.00%	$82.57K

Top Buyers

Holder	Shares	% Assets	Change
Millennium management	119.46K	0.00%	79.96K
Goldman sachs group	61.57K	0.00%	61.57K
Citadel advisors	14.94K	-	14.94K
Baldwin brothers llc/ma	168.63K	0.08%	14.50K
Forbes j m & co llp	47.42K	0.03%	13.42K

Top Sellers

Holder	Shares	% Assets	Change
Blackrock	83.41K	-	-289.31K
State street	15.30K	-	-114.08K
Geode capital management	53.23K	-	-81.30K
Vanguard group	251.14K	-	-47.66K
Morgan stanley	10.20K	-	-30.99K

New Positions

Holder	Shares	% Assets	Change	Value
Goldman sachs group	61.57K	0.00%	61.57K	$389.74K
Citadel advisors	14.94K	-	14.94K	$94.55K
Baxter bros	12.50K	0.01%	12.50K	$79.13K
Qube research	7.98K	0.00%	7.98K	$50.50K
Macquarie group	355.00	-	355.00	$2.25K

Sold Out

Holder	Change
Nelson, van denburg & campbell wealth management group	-1.00
Gamma investing	-25.00
Amalgamated bank	-231.00
Royal bank of canada	-270.00
Trust co of vermont	-500.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2024	38	-5.00%	1,204,111	-22.91%	7	9.04%	25	13.64%	11	-
Mar 31, 2024	40	11.11%	1,561,981	3.22%	8	10.16%	22	4.76%	11	83.33%
Dec 31, 2023	36	9.09%	1,513,319	18.48%	9	13.27%	21	40.00%	6	-53.85%
Sep 30, 2023	33	-10.81%	1,277,304	1.95%	8	11.62%	15	-57.14%	13	550.00%
Jun 30, 2023	37	184.62%	1,252,927	158.91%	8	78.78%	35	218.18%	2	100.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	231.04K	1.22%	-
Vanguard Institutional Extnd Mkt Idx Tr	57.03K	0.31%	-
Fidelity Extended Market Index	38.70K	0.21%	11.17K
iShares Micro-Cap ETF	21.22K	0.11%	-
NT R2000 Growth Index Fund - NL	20.57K	0.11%	-
NT R2000 Index Fund - NL	13.99K	0.07%	-5.76K
Fidelity Total Market Index	13.36K	0.07%	8.99K
The Vanguard Russell 2000 Growth Index	12.03K	0.06%	-
NT R2000 Growth Index Fund - L	11.40K	0.06%	-3.64K
Northern Trust Russell 2000 Growth Index	11.40K	0.06%	-3.64K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Nov 15, 2024	BENTSUR RON	Chairman & CEO	Buy	$98.40K
Nov 07, 2024	Carson Michael J.	Vice President, Finance	Sell	$22.48K
May 14, 2024	BENTSUR RON	Chairman & CEO	Buy	$13.08K
May 10, 2024	BENTSUR RON	Chairman & CEO	Buy	$12.80K
May 10, 2024	Poradosu Enrique	Chief Science & Business Off	Buy	$3.15K

Insider Transactions Trends

Date	Buy	Sell
2024 Q4	-	1
2024 Q3	-	-
2024 Q2	4	-
2024 Q1	1	-
2023 Q4	5	-

NVCT Ownership FAQ

Who Owns Nuvectis Pharma?

Nuvectis Pharma shareholders are primarily institutional investors at 7.27%, followed by 51.41% insiders and 41.32% retail investors. The average institutional ownership in Nuvectis Pharma's industry, Biotech Stocks , is 44.97%, which Nuvectis Pharma falls below.

Who owns the most shares of Nuvectis Pharma?

Nuvectis Pharma’s largest shareholders are Vanguard group (251.14K shares, 1.52%), Baldwin brothers llc/ma (168.63K shares, 1.02%), and Millennium management (119.46K shares, 0.72%). Together, they hold 3.26% of Nuvectis Pharma’s total shares outstanding.

Does Blackrock own Nuvectis Pharma?

Yes, BlackRock owns 0.50% of Nuvectis Pharma, totaling 83.41K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 528K$. In the last quarter, BlackRock decreased its holdings by -289K shares, a -77.62% change.

Who is Nuvectis Pharma’s biggest shareholder by percentage of total assets invested?

Baldwin brothers llc/ma is Nuvectis Pharma’s biggest shareholder by percentage of total assets invested, with 0.08% of its assets in 168.63K Nuvectis Pharma shares, valued at 1.07M$.

Who is the top mutual fund holder of Nuvectis Pharma shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Nuvectis Pharma shares, with 1.22% of its total shares outstanding invested in 231.04K Nuvectis Pharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools